Department of Neuroscience, Cell Biology and Anatomy, School of Medicine, Sealy Center for Structural Biology and Molecular Biophysics , University of Texas Medical Branch , Galveston , Texas 77555 , United States.
Biochemistry. 2019 Mar 12;58(10):1432-1439. doi: 10.1021/acs.biochem.8b01266. Epub 2019 Feb 21.
Chemokines play important roles in immune defense by directing migration of leukocytes and serve as key promoters of tumorigenesis and metastasis. This study explores the molecular mechanisms of recognition and activation of two homologous chemokine receptors, CXCR1 and CXCR2, using CXCL8 analogues with residue substitutions in the conserved Glu4Leu5Arg6 (ELR) triad. Analysis of the binding of CXCL8 analogues to CXCR1 is consistent with the two-site model for signal recognition of CXCR1, whereas analysis of the binding of CXCL8 analogues to CXCR2 supported a single-site model for signal recognition of CXCR2. The CXCL8-Arg6His analogue stimulated calcium release, phosphorylation of ERK1/2, and chemotaxis in cells expressing CXCR1. However, CXCL8-Arg6His failed to stimulate calcium release and chemotaxis in cells expressing CXCR2, although it stimulated phosphorylation of ERK1/2, indicating that CXCL8-Arg6His operated as a classical CXCR2 biased agonist. The CXCL8-Glu4AlaLeu5AlaArg6His analogue was inactive in cells expressing CXCR1 and CXCR2. These findings suggest that the Glu4Leu5 motif in CXCL8 is essential for activation of CXCR1 and CXCR2. Importantly, CXCL8-Glu4AlaLeu5AlaArg6His blocked specifically the calcium release and chemotaxis of cells expressing CXCR1 but not of cells expressing CXCR2. CXCL8-Glu4AlaLeu5AlaArg6His was identified as the first specific CXCR1 antagonist. The binding of CXCL8-ELR6H to CXCR1 created a Zn coordination site at the receptor activation domain responsible for calcium release, as ZnCl specifically blocked CXCL8-Arg6His-induced calcium release without affecting CXCL8-induced calcium release. This work provides the basis for further exploration of the activation mechanisms of chemokine receptors and will assist in the design of the next generation of modulators of CXCR1 and CXCR2.
趋化因子在免疫防御中通过引导白细胞的迁移发挥重要作用,并作为肿瘤发生和转移的关键促进剂。本研究使用在保守的 Glu4Leu5Arg6(ELR)三联体中具有残基取代的 CXCL8 类似物,探索了两种同源趋化因子受体 CXCR1 和 CXCR2 的识别和激活的分子机制。对 CXCL8 类似物与 CXCR1 结合的分析与 CXCR1 信号识别的双位点模型一致,而对 CXCL8 类似物与 CXCR2 结合的分析支持 CXCR2 信号识别的单点模型。CXCL8-Arg6His 类似物刺激表达 CXCR1 的细胞中的钙释放、ERK1/2 的磷酸化和趋化性。然而,CXCL8-Arg6His 未能刺激表达 CXCR2 的细胞中的钙释放和趋化性,尽管它刺激了 ERK1/2 的磷酸化,表明 CXCL8-Arg6His 作为经典的 CXCR2 偏向激动剂起作用。CXCL8-Glu4AlaLeu5AlaArg6His 类似物在表达 CXCR1 和 CXCR2 的细胞中无活性。这些发现表明,CXCL8 中的 Glu4Leu5 基序对于 CXCR1 和 CXCR2 的激活是必需的。重要的是,CXCL8-Glu4AlaLeu5AlaArg6His 特异性阻断表达 CXCR1 的细胞但不阻断表达 CXCR2 的细胞的钙释放和趋化性。CXCL8-Glu4AlaLeu5AlaArg6His 被鉴定为第一个特异性 CXCR1 拮抗剂。CXCL8-ELR6H 与 CXCR1 的结合在受体激活结构域中创建了一个 Zn 配位位点,负责钙释放,因为 ZnCl 特异性阻断 CXCL8-Arg6His 诱导的钙释放而不影响 CXCL8 诱导的钙释放。这项工作为进一步探索趋化因子受体的激活机制提供了基础,并将有助于设计下一代 CXCR1 和 CXCR2 的调节剂。